Objective: The study aimed at evaluating the measurement of serum levels ProGRP in cancer prostate patients to assess their clinical value and to help predicting prognosis in such patients as well as to compare between serum ProGRP, CgA and PSA as useful markers for prostatic carcinoma.Material and Methods: Two groups were included in the study recruiting 81 patients: the first group comprised 54 subjects with pathologically proved prostatic carcinoma and the second group consisted of 27 subjects with benign prostatic hyperplasia. All patients were subjected to measurement of serum urea and creatinine, total and free PSA, CgA, as well as ProGRP along with histopathologic examination of prostate core biopsies obtained by trans-rectal ultrasound (TRUS).Results: There was a statistical significance (P=0.000) was found to exist between the carcinoma and the hyperplasia group as regarding the median level of serum ProGRP . The highest median of serum ProGRP level was observed in the untreated stage D group (49pg/ml). This level was statistically significantly higher than that observed in all other groups with a P value of 0.000. Regarding the other marker CgA a highly significant difference (P=0.002) between, the median value of CgA serum level in the begnin hyperplastic group and in the malignant group. The highest median CgA level was observed in the untreated stage D group. Comparison among groups revealed a significant difference between this group in one hand and all the other group in the other hand; the median level of the begnin group (P=0.000), untreated stage B, C (P=0.000), treated stage B, C was (P=0.002) and treated stage D (P=0.001).A positive correlation was found between ProGRP and CgA in stage D (P=0.001), and a positive correlation was found between ProGRP and PSA in stage D (P=0.005). Conclusions: The neuropeptide precursor ProGRP is a distinct serum marker that is useful to know the neuroendocrine milieu and provides prognostic information in patients with advanced prostate cancer.